Effects of Combined Simultaneous and Sequential Endostar and Cisplatin Treatment in a Mice Model of Gastric Cancer Peritoneal Metastases.

. Aimed to study the effects of endostar and cisplatin using an in vivo imaging system (IVIS) in a model of peritoneal metastasis of gastric cancer. . NUGC-4 gastric cancer cells transfected with luciferase gene (NUGC-4-Luc) were injected i.p. into nude mice. One week later， mice were randomly injected i.p.: group 1， cisplatin (d1-3) + endostar (d4-7); group 2， endostar (d1-4) + cisplatin (d5-7); group 3， endostar + cisplatin d1， 4， and 7; group 4， saline for two weeks. One week after the final administration， mice were sacrificed. Bioluminescent data， microvessel density (MVD)， and lymphatic vessel density (LVD) were analyzed. . Among the four groups， there were no significant differences in the weights and in the number of cancer cell photons on days 1 and 8 ( > 0.05). On day 15， the numbers in groups 3 and 1 were less than that in group 2 ( < 0.05). On day 21， group 3 was significantly less than group 2 ( < 0.05). MVD of group 4 was less than that of groups 1 and 2 ( < 0.01). There was no significant difference between groups 2 and 3 ( > 0.05) or in LVD number among the four groups ( > 0.05). . IVIS® was more useful than weight， volume of ascites， and number of peritoneal nodules. The simultaneous group was superior to sequential groups in killing cancer cells and inhibiting vascular endothelium. Cisplatin-endostar was superior to endostar-cisplatin in killing cancer cells， while the latter in inhibiting peritoneal vascular endothelium.